SG Americas Securities LLC Takes $210,000 Position in Liquidia Co. (NASDAQ:LQDA)

SG Americas Securities LLC bought a new stake in shares of Liquidia Co. (NASDAQ:LQDA) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 20,995 shares of the company’s stock, valued at approximately $210,000.

A number of other hedge funds have also recently modified their holdings of LQDA. Patient Square Capital LP bought a new position in shares of Liquidia during the first quarter valued at approximately $105,942,000. Farallon Capital Management LLC bought a new position in Liquidia in the first quarter worth approximately $30,311,000. BNP Paribas Financial Markets grew its stake in Liquidia by 119.4% in the first quarter. BNP Paribas Financial Markets now owns 230,248 shares of the company’s stock worth $3,396,000 after purchasing an additional 125,315 shares in the last quarter. HighVista Strategies LLC bought a new position in Liquidia in the second quarter worth approximately $1,461,000. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new position in Liquidia in the first quarter worth approximately $1,755,000. Institutional investors own 64.54% of the company’s stock.

Liquidia Trading Up 1.0 %

Shares of LQDA opened at $11.20 on Wednesday. Liquidia Co. has a 12 month low of $6.04 and a 12 month high of $16.99. The stock has a fifty day moving average price of $10.35 and a 200-day moving average price of $11.83. The firm has a market cap of $855.84 million, a PE ratio of -7.18 and a beta of 0.22.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). Liquidia had a negative net margin of 755.46% and a negative return on equity of 183.57%. The business had revenue of $3.66 million for the quarter, compared to analysts’ expectations of $7.92 million. As a group, research analysts forecast that Liquidia Co. will post -1.69 EPS for the current year.

Insider Activity

In other news, insider Rajeev Saggar sold 2,260 shares of the stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $25,108.60. Following the completion of the sale, the insider now owns 207,383 shares in the company, valued at approximately $2,304,025.13. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Liquidia news, Director Caligan Partners Lp purchased 150,000 shares of Liquidia stock in a transaction on Friday, August 30th. The stock was bought at an average cost of $9.51 per share, with a total value of $1,426,500.00. Following the transaction, the director now owns 6,994,997 shares of the company’s stock, valued at $66,522,421.47. This represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Rajeev Saggar sold 2,260 shares of Liquidia stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $25,108.60. Following the sale, the insider now owns 207,383 shares of the company’s stock, valued at approximately $2,304,025.13. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 23,384 shares of company stock worth $256,990. Insiders own 31.60% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on LQDA. Lifesci Capital began coverage on Liquidia in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 price objective on the stock. Scotiabank began coverage on Liquidia in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price objective on the stock. Bank of America dropped their price objective on Liquidia from $24.00 to $23.00 and set a “buy” rating on the stock in a research note on Tuesday, August 20th. Raymond James upgraded Liquidia from an “outperform” rating to a “strong-buy” rating in a report on Monday, August 19th. Finally, HC Wainwright lowered their target price on Liquidia from $32.00 to $29.00 and set a “buy” rating for the company in a report on Tuesday, August 20th. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $24.67.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).